Case Report

Tibia Adamantinoma Resection and Reconstruction with a Custom-Made Total Tibia Endoprosthesis: A Case Report with 8-Year Follow-Up

Gilber Kask,1 Toni-Karri Pakarinen,1 Jyrki Parkkinen,2 Hannu Kuokkanen,3 Jyrki Nieminen,4 and Minna K. Laitinen1

1Department of Orthopaedics and Traumatology, Unit of Musculoskeletal Surgery, Tampere University Hospital, Teiskontie 35, 33521 Tampere, Finland
2Fimlab Laboratories, Arvo Ylpön katu 4, 33520 Tampere, Finland
3Division of Plastic Surgery, Helsinki University Central Hospital, Tapeliuksenkatu 5, 00260 Helsinki, Finland
4Coxa Hospital for Joint Replacement, Biokatu 6, 33520 Tampere, Finland

Correspondence should be addressed to Gilber Kask; gilber.kask@gmail.com

Received 17 March 2018; Accepted 24 April 2018; Published 6 June 2018

Academic Editor: Wan Ismail Faisham

Copyright © 2018 Gilber Kask et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This case study describes a total tibia resection and reconstruction with a custom-made endoprosthetic replacement (EPR) and a long-term, 8-year follow-up. The patient underwent a total tibia adamantinoma resection in 2009. Reconstruction was performed with a custom-made total tibia EPR, where both the knee joint and ankle joint were reconstructed. Two muscle flaps, latissimus dorsi free flap and a pedicled medial gastrocnemius flap, were used for soft tissue reconstruction. The patient returned to normal life as a kindergarten teacher, without complications for eight years. This case demonstrated the importance of successful multidisciplinary teamwork in close collaboration with industry. In our best knowledge, no over 2 years of follow-up of total tibia replacement reports have been published.

1. Introduction

Adamantinoma is a rare malignant bone tumor, accounting for approximately 0.1–0.5% of all primary bone tumors [1]. There is a slight male predominance [1–3]. Tibia is involved in 85–90% of cases, but the other sites, including the fibula, ulna, femur, humerus, and radius, have been also reported [2, 4].

There have been no definitive guidelines for a treatment of adamantinoma. The preferred treatment is surgical management with wide margins, reconstruction if necessary and possible, or amputation [1]. Methods of limb salvage with reconstruction include distraction osteogenesis, allografts, vascularized fibular autografts, nonvascularized autogenous bone grafts, or endoprosthetic reconstructions (EPRs) [5]. Chemotherapy and radiotherapy in adamantinoma treatment have not been shown to be effective [2, 6, 7], and therefore surgery remains the only curative option. After successful surgery with wide margins, the overall 10-year survival rates vary from 82% to 87% [1, 6]. In the literature, reported limb salvage rate for long bone adamantinoma patients is about 84% [3] and amputation compared with the limb preserving surgery has not been proved to improve survival rate [5].

Reconstruction after resection surgery for adamantinoma, in long bones, is dependent on the site and size of tumor. In the most common site, tibia, reconstruction is often EPR which is associated with a high rate of complications (48%) [3]. One of the most serious complication in EPR surgery is a periprosthetic joint infection (PJI). Deep infection in EPR around the knee is reported to be 4–45% [8]. Furthermore, limb reconstruction with extensive customized endoprosthesis is associated with an even higher incidence of serious complications. PJI is the main indication for a secondary amputation in EPR of the proximal tibia [9].
In cases where tumor affects the entire tibia, a wide excision with a clear margin is achievable with knee disarticulation, or higher amputation, or with a total tibia resection and reconstruction. In the current literature, only two cases of total tibia reconstruction have been published [10, 11]. One total EPR had a short follow-up of two years without early complications, and one case was reconstructed with a total tibia allograft, subsequently ending in a complication leading to amputation. To our best knowledge, no midterm or long-term results over 2 years of follow-up of total tibia replacement case reports have been published.

This study describes a case of complete tibia resection and total tibia custom-made EPR, with a long-term follow-up and functional outcome. This case study highlights the rarity of the reconstruction, multidisciplinary team work, and the good long-term functional result.

2. Case Presentation

A 48-year-old female with known breast carcinoma was screened for possible dissemination with whole-body computed tomography (CT) and a bone scintigraphy scan. The bone scan revealed a tumor in the entire right tibia. The patient reported no symptoms from the tibia tumor. A plain X-ray and magnetic resonance image (MRI) confirmed an intraosseal tumor that extended from 4 cm below the knee joint proximally to about 4 cm from the ankle joint distally (Figure 1). An open biopsy confirmed an adamantinoma histology. Different treatment options were thoroughly discussed with the patient, including a lower leg amputation with disarticulation of the knee, a total tibia resection and reconstruction with a tibia allograft, or a custom-made tibia EPR, which was eventually selected.

The tumor was resected with an extensive anteromedial approach, and the defect was reconstructed with a custom-made, silver-coated, modular endoprosthesis of the Modular Universal Tumor and Revision System (Implantcast®, Buxtehude, Germany) (Figure 2). The knee joint was reconstructed with a metal-on-poly articulation with a (unique) metal-on-metal hinge mechanism (Figure 3). The ankle joint was reconstructed with a metal-on-poly hinge joint with a talar replacement, stabilized with a trans-talar and trans-calcaneal hydroxyapatite-coated stem. A supplementary screw was used to add stability in the subtalar joint. The endoprosthesis was enveloped in a Trevira (Implantcast®) tube to facilitate the attachment of soft tissues and the patella tendon (Figure 4). A microvascular latissimus dorsi musculocutaneous flap was anastomosed to the tibia artery (end-to-side) and concomitant vein and wrapped around the prosthesis to avoid dead space and allow tension-free closure. In addition, a medial gastrocnemius muscle flap was transposed to cover the patellar tendon region; this was covered with a meshed split-thickness skin graft.

A histological analysis of the resected specimen showed an adamantinoma that had spread throughout the entire tibia and the margins were wide: an unaffected periosteum as an anatomic barrier and a minimum of clear soft tissue margin of 3 mm. Due to intracortical location of the tumor, no massive muscle excision was needed.

The knee joint was immobilized in extension for 6 weeks to facilitate patella ligament attachment to the tube. Then, the joint was gradually mobilized. After 6 months, the patient’s gait was almost normal, with mild limping. Local MRI and chest radiographs performed during the 8 years of follow-up showed no signs of local recurrence or distant metastasis. No loosening of the stem or other mechanical problem was reported. In a routine follow-up, in addition to radiographs, we used a local MRI with a metal artifact reduction sequence (MARS) technique [12], which enables to observe local recurrences of the tumor around the massive titanium endoprostheses.

Eight years postoperatively, the patient had most of the time no pain and could mobilize freely. The patient resumed working full-time as a kindergarten teacher, and she has maintained her previous active lifestyle (except downhill skiing). On her latest follow-up visit (at 8 years), the knee range of motion was 0–105 degrees, ankle dorsiflexion was 5 degrees, and ankle flexion was 35 degrees. In the latest follow-up visit, we used 4 patient-related outcome (PRO) measures. The Musculoskeletal Society Tumor Score (MSTS) was 77%; the Oxford Knee score (OKS) was 35/48; the Toronto Extremity Salvage Score (TESS) was 80/100; and the 15D was 0.87/1.

The metal-on-metal prosthesis caused an increase in metal ion concentrations: cobalt was 6 ppb and chromium was 8 ppb. The silver coating created a mild, local skin argyria pigmentation, with cosmetic discomfort [13] (Figure 5).
3. Discussion

Due to the subcutaneous location of the tibia and its close proximity to vital neurovascular and musculotendinous structures, limb salvage surgery can be difficult to achieve in tibia bone malignancies. Complication rates are higher in the proximal and distal tibia than at other locations, and they are highest with total tibia reconstructions [8]. PJIs, particularly in tibia locations, comprise the main indication for a secondary amputation. The 10-year implant survival rates are reported to be 40–74%, following tumor resection and reconstruction with different types of EPRs. However, those studies mostly investigated implant survival for fixed- or rotating-hinge knee prostheses, with some total femoral prostheses, but none investigated a total tibia replacement [9].

In our opinion, it is essential to use a well-vascularized flap after implant reconstruction. Muscle flaps have demonstrated good adherence to implants, and thus they resist seroma formation and lower the risk of infection. Technically, a free flap is relatively easy to use in the primary operation, because vascular structures are well exposed.

The soft tissue reconstruction is very important to prevent infection complications. In present case, a free latissimus dorsi flap was wrapped around the prosthesis to avoid dead space. Rotational medial gastrocnemius was used to cover the defects. In preankle area, it is very important to avoid dead space, cover the defects and get good vascularity, to prevent infection.
The antimicrobial activity of silver has gained interest in the orthopaedic community, especially among orthopaedic surgeons using megaendoprostheses. The main advantage of using silver-coated EPR includes the reduction of the incidence of PJI with a low level of toxicity [14–16]. Several side effects in silver-coated implants have been reported, including argyria, as seen in our patient, kidney and liver damage, leukopenia, and toxicity in neural tissues. The systemic effects have been reported with blood concentrations exceeding 300 ppb. In large clinical series of silver-coated EPR, silver levels in blood samples did not exceed 56 ppb and were considered nontoxic [17, 18]. Local asymptomatic argyria has been described to occur even in 23% of patients with silver-coated EPR [19].

Eight years postoperatively, the patient resumed working full-time as a kindergarten teacher, and except downhill skiing, she has maintained her previous active lifestyle. On her latest follow-up visit, the motions of knee and ankle ranges were good. In addition, we used 4 PRO measures in the latest follow-up visit (MSTS, OKS, TESS, and 15D). Based on these measures, patient had some limitations in walking and participating in usual leisure activities. She had mild pain from the knee, limping problems, and impossibility to kneel. In addition, patient had moderate difficulties in putting shoes on, gardening, getting in and out of the bath, walking upstairs and downstairs, and getting out of a car. The 15D questionnaire showed that patient had mild sleeping problems and mild sadness. In our opinion, patient’s overall functional outcome was good.

Local MRI with a MARS technique enables to observe local recurrences of the tumor around the massive titanium endoprostheses. This technique reduces the artifacts caused by endoprosthesis, improves the quality of the images at the periprosthetic region, and leads to reliable diagnosis of endoprosthesis-related problems [12].

Due to the rarity of a total tibia EPR, we could identify only one previous case report with a relatively short follow-up. In the literature case report [11], a total tibia EPR was performed for a patient with Ewing sarcoma. They described a 2-year follow-up, with no early-stage complications. In addition, another study has presented a 17-year follow-up of tibia replacement [20]. However, in this osteosarcoma case report, it was not a total tibia replacement as no total ankle joint replacement was made, since part of the distal tibia was not removed. Anterior part of the ankle is a critical location for complications, because of the movement and subcutaneous position of the joint. Also, one reconstruction with a total tibia allograft has been published [10]. In this report, eight months after the surgery, the patient reappeared with rapidly increased pain and the allograft was fractured. About 1 year after the initial diagnosis, a knee disarticulation was performed and the patient was supplied with an exoprosthesis. In this case, authors have discussed that using a prosthesis system instead of the allograft might have saved the limb of their patient [10].

The present report demonstrated that a complex total tibia EPR is feasible with a functionally good outcome. It is important to use a well-vascularized flap after implant reconstruction. Technically, a free flap is relatively easy to use in the primary operation. Muscle flaps have demonstrated good adherence to implants: they resist seroma formation and decrease the risk of infection. However, we emphasize that long-term success required a multidisciplinary team working closely in collaboration with the endoprosthesis industry.

Consent
The patient has given informed consent for the case report to be published.

Conflicts of Interest
The authors declare that they have no conflicts of Interest.

Authors’ Contributions
Gilber Kask and Minna K. Laitinen analyzed and interpreted the patient data regarding the oncological disease and the surgery. Surgery was performed by Minna K. Laitinen, Toni-Karri Pakarinen, Hannu Kuokkanen, and Jyrki Nieminen. Jyrki Parkkinen performed the histological examination of the tumor. Gilber Kask and Minna K. Laitinen were a major contributor in writing the manuscript. Minna K. Laitinen, Toni-Karri Pakarinen, and Jyrki Nieminen provided writing assistance. All authors read and approved the final manuscript.

References
[1] P. J. Papagelopoulos, A. F. Mavrogenis, E. C. Galanis, O. D. Savvidou, C. Y. Inwards, and F. H. Sim, “Clinicopathological features, diagnosis, and treatment of adamantinoma of the long bones,” Orthopedics, vol. 30, pp. 211–215, 2007.
[2] M. Szendrői, I. Antal, and G. Arató, “Adamantinoma of long bones: a longterm follow-up study of 11 cases,” Pathology Oncology Research, vol. 15, no. 2, pp. 209–216, 2009.
[3] A. A. Qureshi, S. Shott, B. A. Mallin, and S. Gitelis, “Current trends in the management of adamantinoma of long bones,” The Journal of Bone and Joint Surgery-American Volume, vol. 82, no. 8, pp. 1122–1131, 2000.
[4] V. Y. Jo and C. D. M. Fletcher, “WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition,” Pathology, vol. 46, no. 2, pp. 95–104, 2014.
[5] D. Jain, V. K. Jain, R. K. Vasishta, P. Ranjan, and Y. Kumar, “Adamantinoma: a clinicopathological review and update,” Diagnostic Pathology, vol. 3, no. 1, p. 8, 2008.
[6] G. L. Keeney, K. K. Unni, J. W. Beabout, and D. J. Pritchard, “Adamantinoma of long bones. A clinicopathologic study of 85 cases,” Cancer, vol. 64, no. 3, pp. 730–737, 1989.
[7] C. Khémiri, D. Mrabet, H. Mizouni et al., “Adamantinoma of the tibia and fibula with pulmonary metastasis: an unusual presentation,” BMJ Case Reports, vol. 2011, no. oct16 1, p. bcr0620114318, 2011.
[8] T. Morii, H. Morioka, T. Ueda et al., “Deep infection in tumor endoprostheses around the knee: a multi-institutional study by the Japanese musculoskeletal oncology group,” BMC Musculoskeletal Disorders, vol. 14, no. 1, p. 51, 2013.
[9] G. J. C. Myers, A. T. Abudu, S. R. Carter, R. M. Tillman, and R. J. Grimer, “The longterm results of endoprosthetic replacement of the proximal tibia for bone tumours,” The Journal of
[10] S. P. Frey, J. Hardes, H. Ahrens, W. Winkelmann, and G. Gosheger, "Total tibia replacement using an allograft (in a patient with adamantinoma). Case report and review of literature," *Journal of Cancer Research and Clinical Oncology*, vol. 134, no. 4, pp. 427–431, 2008.

[11] G. Gosheger, J. Hardes, B. Leidinger et al., "Total tibial endoprosthesis including ankle joint and knee joint replacement in a patient with Ewing sarcoma," *Acta Orthopaedica*, vol. 76, no. 6, pp. 944–946, 2005.

[12] D. Yue, C. Fan Rong, C. Ning et al., "Reduction of metal artifacts from unilateral hip arthroplasty on dual-energy CT with metal artifact reduction software," *Acta Radiologica*, vol. 59, no. 7, pp. 853–860, 2018.

[13] V. Alt, "Antimicrobial coated implants in trauma and orthopaedics—a clinical review and risk-benefit analysis," *Injury*, vol. 48, no. 3, pp. 599–607, 2017.

[14] J. Hardes, C. von Eiff, A. Streitbuerger et al., "Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma," *Journal of Surgical Oncology*, vol. 101, no. 5, pp. 389–395, 2010.

[15] J. Hardes, M. P. Henrichs, G. Hauschild, M. Nottrott, W. Guder, and A. Streitbuerger, "Silver-coated megaprostheses of the proximal tibia in patients with sarcoma," *The Journal of Arthroplasty*, vol. 32, no. 7, pp. 2208–2213, 2017.

[16] H. Wafa, R. J. Grimer, K. Reddy et al., "Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients," *The Bone & Joint Journal*, vol. 97-B, no. 2, pp. 252–257, 2015.

[17] J. Hardes, H. Ahrens, C. Gebert et al., "Lack of toxicological side-effects in silver-coated megaprostheses in humans," *Biomaterials*, vol. 28, no. 18, pp. 2869–2875, 2007.

[18] T. Schmidt-Braekling, A. Streitbuerger, G. Gosheger et al., "Silver-coated megaprostheses: review of the literature," *European Journal of Orthopaedic Surgery & Traumatology*, vol. 27, no. 4, pp. 483–489, 2017.

[19] M. Glehr, A. Leithner, J. Friesenbichler et al., "Argyria following the use of silver-coated megaprostheses: no association between the development of local argyria and elevated silver levels," *The Bone & Joint Journal*, vol. 95-B, no. 7, pp. 988–992, 2013.

[20] R. D. Burghardt, D. Kendoff, W. Klauser, H. Mau, and T. Gehrke, "A 17-year follow-up after total tibial replacement in the course of an osteosarcoma followed by total leg replacement," *Journal of Knee Surgery Reports*, vol. 1, no. 01, pp. 044–050, 2015.
